At a data cut-off of 37.3 months, EFS improved to 3.4 months for crenolanib, compared with 0.0 months for placebo.

Later-stage financing deals for cell and gene therapy companies reflects a broader derisking trend in the pharma industry.

The Alabama facility is part of the $27bn investment Eli Lilly has pledged to expand its US footprint. American pharmaceutical giant Eli Lilly has tapped Huntsville, Alabama, as the location for its ...

Formycon and Zydus Lifesciences have entered into an exclusive licensing and supply agreement for FYB206 in the US and Canada ...

Biogen has received an NOC from Health Canada for Zurzuvae, a NAS, as a treatment for moderate or severe PPD in women.

As Datwyler unveils its next-generation flip cap made with bio-based polypropylene, we spoke with Camille Ermine about the challenges and opportunities of eco-design in parenteral packaging, from ...

Relapsed or refractory (R/R) follicular lymphoma (FL) remains a therapeutic challenge despite recent advances. Credit: evan_huang via Shutterstock. Bristol Myers Squibb’s golcadomide, a first-in-class ...

The deal gives Mirum access to Bluejay’s monoclonal antibody brelovitug, which is currently in Phase III trials.

This comes just under a month after Pfizer finalised a deal to acquire Metsera following a bidding war with Novo Nordisk.

The bipolar disorder (BD) market across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and ...

Roche has received EC approval for its humanised monoclonal antibody Gazyva, in combination with mycophenolate mofetil (MMF).

Inductive Bio has secured up to $21m in funding from ARPA-H to lead the development of AI drug-toxicity prediction models.